National Government Services Issues Positive Coverage for Percutaneous Tibial Nerve Stimulation

MINNEAPOLIS, Aug. 11, 2014 -- Uroplasty, Inc. (UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services (NGS) has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB).  Coverage for the proprietary Urgent PC® device was effective August 10, 2014.

NGS, a Medicare Administrative Contractor, provides medical and drug benefits to approximately 10 million Medicare beneficiaries in the states of New York, Illinois, Massachusetts, Wisconsin, Minnesota, Connecticut, Maine, New Hampshire, Rhode Island and Vermont.

Alpha Pro Tech, Ltd. Announces Financial Results for the Second Quarter Ended June 30, 2014

Consolidated Sales Increased 10% to $12.3 Million in Second Quarter
Income from Operations Increased 48% for the Second Quarter to $1.03 Million

NOGALES, Ariz.-- Alpha Pro Tech, Ltd.:

• Disposable Protective Apparel segment sales for the three months ended June 30, 2014, increased 24.2% to $3.8 million, compared to $3.1 million for the same period of 2013.
• Selling, general and administrative expenses decreased to 26.9% of sales for the quarter ended June 30, 2014, compared to 28.5% for the quarter ended June 30, 2013.
• Net income increased 88.8% to $895,000 for the quarter ended June 30, 2014, compared to $474,000 for the quarter ended June 30, 2013.
• Basic and diluted earnings per common share for the quarters ended June 30, 2014 and 2013 were $0.05 and $0.02, respectively.

TSO3 announces financial results for second quarter 2014

QUEBEC CITY, Aug. 5, 2014  - TSO₃ Inc. ("TSO₃") (TSX:TOS.TO) an innovator in low temperature sterilization technology for medical devices in healthcare settings, today reported its financial results for the second quarter (Q2) ended June 30, 2014.

In Q2-2014, sales amounted to $132,179, as compared to $37,255 in the second quarter in 2013. For the six-month period ended June 30, 2014, sales were $213,936, as compared to $113,314 for the same period in 2013. The higher sales in 2014 reflect a higher utilization by the users of the installed base of sterilizers leading to increased sales of consumables, as well as an increase in maintenance and compatibility testing services.

Tandem Diabetes Care Reports Second Quarter 2014 Financial Results

SAN DIEGO, July 31, 2014 -- Tandem Diabetes Care®, Inc. (TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today reported its financial results for the quarter ended June 30, 2014.

In comparing the second quarter of 2014 to the same period of 2013:

• Sales grew 86 percent to $10.3 million from $5.5 million
• t:slim Pump shipments grew 64 percent to 2,235 pumps from 1,363 pumps